NCT01140347 · MORE INFO

Limitations, agreements, and source contact

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib · Source last updated 2015-12-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

organization: Eli Lilly and Company
phone: 800-545-5979
title: Chief Medical Officer

Complete source fields

certain Agreement

other Details: Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

organization: Eli Lilly and Company
phone: 800-545-5979
title: Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice